Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: A randomized, controlled trial

Simple item page
dc.contributor.authorBaran, Çağdaş
dc.contributor.authorDurdu, Serkan
dc.contributor.authorDalva, Klara
dc.contributor.authorZaim, Çağın
dc.contributor.authorDoğan, Arin
dc.contributor.authorGürman, Günhan
dc.contributor.authorArslan, Önder
dc.contributor.authorAkar, Ahmet Ruchan
dc.contributor.buuauthorOcakoğlu, Gökhan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-5180-2021tr_TR
dc.contributor.scopusid15832295800tr_TR
dc.date.accessioned2021-11-26T06:41:25Z
dc.date.available2021-11-26T06:41:25Z
dc.date.issued2012-09
dc.description.abstractWe investigated the effects of short-term use of atorvastatin on CD34+/VEGF-R2+/CD133+/CD45- endothelial progenitor cell (EPC) count after on-pump coronary artery bypass surgery (CABG). Between Feb-2010 and May-2010, we randomly assigned, in a placebo-controlled, double-blind study, 60 consecutive patients who underwent isolated, first-time CABG to receive either 14-day atorvastatin (40 mg/day) or placebo preoperatively. Urgent CABG and recent myocardial infarction were excluded. EPCs were quantified (cells/mu l) by flow cytometric phenotyping obtained from venous blood samples collected preoperatively (T-1), 6-hours (T-2), and on the 5th day postoperatively (T-3). Levels of markers of inflammation and serum cardiac troponin I were also measured preoperatively and daily until day-5 after surgery. There were no differences in baseline risk factors including cholesterol profiles, and EuroSCORES between the groups. The composite primary end-point, favored statin group with higher amount of circulating, early EPC count (cells/mu l) at all time points compared with placebo (T-1, 2.30 +/- 0.02 versus 1.58 +/- 0.03, p < 0.001; T-2, 5.00 +/- 0.06 versus 2.19 +/- 0.06, p < 0.001; T-3, 3.03 +/- 0.08 versus 1.78 +/- 0.02, p < 0.001). Postoperative hsCRP rise were inversely correlated with EPC count, and were significantly lower in the statin group (T-1, 0.8 +/- 0.1 versus 2.2 +/- 1.5, p < 0.001; T-2, 72.9 +/- 3.2 versus 96.0 +/- 3.6, p < 0.001; T-3, 4.3 +/- 1.2 versus 11.4 +/- 4.1, p < 0.001). Furthermore, the incidence of postoperative atrial fibrillation was significantly lower in the statin group compared to placebo (3.3% versus 23%, p = 0.02). Short-term atorvastatin use increases circulating early EPCs both pre- and post-operatively and is associated with better preservation of sinus rhythm and reduced hsCRP levels.en_US
dc.description.sponsorshipAnkara University School of Medicine Research Council - BAP - B.30.2.ANK.0.05.02.00en_US
dc.identifier.citationBaran, Ç. vd. (2012). "Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: A randomized, controlled trial". Stem Cell Reviews and Reports, 8(3), 963-971.en_US
dc.identifier.endpage971tr_TR
dc.identifier.issn1550-8943
dc.identifier.issue3tr_TR
dc.identifier.pubmed22076751tr_TR
dc.identifier.scopus2-s2.0-84865534163tr_TR
dc.identifier.startpage963tr_TR
dc.identifier.urihttps://doi.org/10.1007/s12015-011-9321-z
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs12015-011-9321-z
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/22076751/
dc.identifier.urihttp://hdl.handle.net/11452/22809
dc.identifier.volume8tr_TR
dc.identifier.wos000307333100030tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherHumana Pressen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalStem Cell Reviews and Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCell biologyen_US
dc.subjectResearch & experimental medicineen_US
dc.subjectEndothelial progenitor cellsen_US
dc.subjectStatinsen_US
dc.subjectCABGen_US
dc.subjectC-reactive proteinen_US
dc.subjectCardiopulmonary bypassen_US
dc.subjectMyocardial damageen_US
dc.subjectPeripheral-blooden_US
dc.subjectCardiac-surgeryen_US
dc.subjectArtery-diseaseen_US
dc.subjectStatin therapyen_US
dc.subjectBone-marrowen_US
dc.subjectAngiogenesisen_US
dc.subjectRegenerationen_US
dc.subjectIncreaseen_US
dc.subject.emtreeAntiinflammatory agenten_US
dc.subject.emtreeAtorvastatinen_US
dc.subject.emtreeC reactive proteinen_US
dc.subject.emtreeHeptanoic acid derivativeen_US
dc.subject.emtreeLipiden_US
dc.subject.emtreePyrrole derivativeen_US
dc.subject.emtreeTroponin Ien_US
dc.subject.emtreeAgeden_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCoronary artery bypass graften_US
dc.subject.emtreeCoronary artery diseaseen_US
dc.subject.emtreeEndotheliumen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePreoperative perioden_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeStem cell transplantationen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAgeden_US
dc.subject.meshAnti-inflammatory agentsen_US
dc.subject.meshC-reactive proteinen_US
dc.subject.meshCoronary artery bypassen_US
dc.subject.meshCoronary artery diseaseen_US
dc.subject.meshEndotheliumen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeptanoic acidsen_US
dc.subject.meshHumansen_US
dc.subject.meshLipidsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPreoperative perioden_US
dc.subject.meshPyrrolesen_US
dc.subject.meshStem cell transplantationen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTroponin Ien_US
dc.subject.scopusEndothelial Progenitor Cells; Acetyl Low Density Lipoprotein; Chemokine CXCL12en_US
dc.subject.wosCell & tissue engineeringen_US
dc.subject.wosCell biologyen_US
dc.subject.wosMedicine, research & experimentalen_US
dc.titleEffects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: A randomized, controlled trialen_US
dc.typeArticle
dc.wos.quartileQ1 (Medicine, research & experimental)en_US
dc.wos.quartileQ2en_US

Files

Collections

Web of Science
Scopus